The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Cassava Sciences (NASDAQ:SAVA – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $2.00 target ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period ...

Charles Schwab Investment Management Inc. cut its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 11.6% in the 4th quarter, according to its most recent filing with the ...

The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...